Haemonetics Q1 Adjusted EPS $1.05 Beats $0.76 Estimate, Sales $311.33M Beat $297.92M Estimate
Portfolio Pulse from Benzinga Newsdesk
Haemonetics (NYSE:HAE) reported Q1 earnings of $1.05 per share, beating the analyst consensus estimate of $0.76 by 38.16%. This is an 81.03% increase from the same period last year. The company also reported quarterly sales of $311.33 million, beating the analyst consensus estimate of $297.92 million by 4.50%. This is a 19.08% increase from the same period last year.
August 08, 2023 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics reported strong Q1 results, beating both earnings and sales estimates. This could potentially lead to a positive market reaction.
Haemonetics reported a significant increase in both earnings per share and sales compared to the same period last year, beating analyst estimates. This strong performance is likely to be viewed positively by the market, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100